Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.53 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495478 | 1.00 | P2RX3 (0.53) | P2RX3P2RX2GAAKMT2AHSD17B10 | |
| SCHEMBL12757521 | 0.91 | P2RX3 (0.59) | P2RX3P2RX2 | |
| SCHEMBL1495533 | 0.86 | P2RX3 (0.55) | P2RX3P2RX2 | |
| SCHEMBL1495532 | 0.86 | P2RX3 (0.55) | P2RX3P2RX2 | |
| SCHEMBL1495757 | 0.84 | P2RX3 (0.53) | P2RX3P2RX2 | |
| SCHEMBL2760885 | 0.84 | P2RX3 (0.53) | P2RX3P2RX2 | |
| SCHEMBL311340 | 0.82 | P2RX3 (0.54) | P2RX3P2RX2 | |
| SCHEMBL2760558 | 0.81 | P2RX3 (0.52) | P2RX3P2RX2 | |
| SCHEMBL8007045 | 0.81 | P2RX3 (0.52) | P2RX3P2RX2 | |
| SCHEMBL1495466 | 0.81 | P2RX3 (0.49) | P2RX3P2RX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2262766-B1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2015-11-11 | — | — | EP | disclosed |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | RENOVIS, INC. | 2015-09-24 | — | — | US | disclosed |
| US-8946439-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-03-17 | — | — | US | disclosed |
| EP-2262766-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | Renovis, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009110985-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065681-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | P2RX3 219/4885P2RX2 259/4885GAA 3106/4885 |
| US-20150266822-A1 | Amide Compounds, Compositions And Uses Thereof | IL1B, ADORA2B, AVPR1B | P2RX3 219/4885P2RX2 259/4885GAA 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.